We have developed our SPOT™ technology alongside our proprietary CHO cell line to increase the cell line specific productivity (Qp) which facilitates high volumetric productivity at low VCD accompanied with a simple and efficient DSP process. Watch our on demand webinar now to find out more.
On Demand Webinar: Looking to develop a high quality, high titer manufacturing cell line?
- Published:
- written by: Polpharma Biologics
Related news
Other news related to this topic that may be of interest to you
Polpharma Biologics confirms U.S. launch of Tyruko® (natalizumab), the first and only biosimilar for Multiple Sclerosis
November 17, 2025 – Polpharma Biologics, a biopharmaceutical company group focused on biosimilars development...
Polpharma Biologics announces commercial launch of Europe’s first Pre-filled Syringe presentation of a ranibizumab biosimilar
Zurich, Switzerland – October 21, 2025 – Polpharma Biologics today announced Ranivisio® PFS (ranibizumab...
Polpharma Biologics is splitting its operations into two independent companies
Polpharma Biologics is splitting its operations into two independent companies, each with a clear focus...
Polpharma Biologics and MS Pharma sign licensing agreements for proposed vedolizumab (PB016), ocrelizumab (PB018) and guselkumab (PB019) biosimilars.
Amsterdam, Gdańsk – September 2nd, 2025 – Polpharma Biologics S.A. (“Polpharma Biologics”), specialized...